Patents Assigned to Julius-Maximilians-Universitat Wurzburg
-
Publication number: 20140370530Abstract: The invention relates to the use of LASP-1 in a urine sample obtained from a subject for diagnosing and/or grading transitional cell carcinoma. The invention furthermore relates to a method for diagnosing transitional cell carcinoma comprising detecting the presence or absence of LASP-1 in a urine sample obtained from a subject, wherein the presence of LASP-1 above 1 ng/500 ?l urine is indicative for transitional cell carcinoma and a method for grading transitional cell carcinoma comprising determining the level of LASP-1 in a urine sample obtained from a subject, wherein the level of LASP-1 correlates with the grade of the transitional cell carcinoma.Type: ApplicationFiled: December 6, 2012Publication date: December 18, 2014Applicant: JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURGInventor: Elke Butt
-
Patent number: 8889425Abstract: Described is a chimeric peptide, comprising, in order, (a) a first detectable label (b) a cAMP binding moiety having only one cAMP binding site and (c) a second detectable label least two detectable labels is describe. The chimeric peptide is useful for direct determination of cAMP concentration in vitro and/or in vivo. Also described are nucleic acids encoding the chimeric peptide, methods of making and modifying the chimeric peptide, a method for determining the cAMP concentration, and kits.Type: GrantFiled: November 26, 2004Date of Patent: November 18, 2014Assignee: Bayerische Julius-Maximilians-Universität WürzburgInventors: Viacheslav Nikolaev, Moritz Bünemann, Martin J. Lohse
-
Patent number: 8877718Abstract: The present invention relates to naphthoquinone derivatives isolated from solid callus cultures from two species of the palaeotropical plant families Dioncophyllaceae and Ancistrocladaceae. It further relates to methods of their production as well as to their use as antiinfective and antitumoral pharmaceuticals.Type: GrantFiled: February 6, 2009Date of Patent: November 4, 2014Assignee: Julius-Maximilians-Universität WürzburgInventors: Gerhard Bringmann, Stefan Rüdenauer, Reto Brun, Andreas Irmer, Ralf Bargou, Manik Chatterjee, Anastasia Voskobojnik
-
Patent number: 8854617Abstract: The present invention relates to compounds and markers for surface-enhanced Raman scattering (SERS), and methods for the preparation of the SERS markers. The present invention further relates to compositions, methods and uses, wherein the present SERS markers are employed.Type: GrantFiled: September 24, 2008Date of Patent: October 7, 2014Assignee: Julius-Maximilians-Universitat WurzburgInventors: Bernd Küstner, Sebastian Schlücker, Carsten Schmuck
-
Publication number: 20140121264Abstract: In some embodiments, the invention is directed to a method for diagnosing fibrosis and/or fibrosis related diseases and to a method for screening a pharmaceutically active compound for the treatment of fibrosis and/or fibrosis related diseases. The present invention further relates to compositions for use in the treatment, amelioration, and/or prevention of fibrosis. In certain embodiments, the compositions modulate the activity of a miRNA for the treatment, amelioration, and/or prevention of fibrosis. In certain embodiments, the compositions inhibit the activity of miR-21 for the treatment, amelioration, and/or prevention of fibrosis.Type: ApplicationFiled: October 23, 2013Publication date: May 1, 2014Applicant: JULIUS-MAXIMILIANS-UNIVERSITAT WURZBURGInventors: Thomas Thum, Johann Bauersachs, Stefan Engelhardt, Carina Gross
-
Publication number: 20140112937Abstract: The present invention relates to the use of a composition selected from the group consisting of antibodies, antibody fragments, insulin-like growth factor antagonists, Toll-like receptor antagonists and mixtures thereof for the treatment or the prophylaxis of certain diseases.Type: ApplicationFiled: March 28, 2012Publication date: April 24, 2014Applicants: FREISTAAT BAYERN REPRESENTED BY JULIUS- -MAXIMILIANS-UNIVERSITAT WURZBURG, MAT-MALTA ADVANCED TECHNOLOGIES LIMITEDInventors: Jan Wesjohann, Günter Sprotte, Ana Maria
-
Publication number: 20140072570Abstract: The invention concerns antibodies or fragments thereof that are directed against a Staphylococcus aureus epitope.Type: ApplicationFiled: November 12, 2013Publication date: March 13, 2014Applicant: JULIUS-MAXIMILIANS-UNIVERSITAT WURZBURGInventors: Knut OHLSEN, Udo LORENZ
-
Patent number: 8665446Abstract: An apparatus and a method for coherent multi-dimensional optical spectroscopy employs a beam splitter for splitting a base light pulse into at least first to fourth light pulses, three of which are suitable for interaction with a sample, lens system focuses the first to fourth light pulses at a sample site, and an optical delay varies the arrival times of the first to fourth light pulses at the sample. A detector detects an interference signal. The beam splitter is a non-diffractive optical element. The light pulses, at least along part of their light paths, are guided pairwisely such that changes in the optical path length due to vibration of the beam splitter or due to the delay element are identical for each pair of pulses, where the pulse pairs compensate for any change in the interference signal due to a change of the arrival times of the pair of pulses.Type: GrantFiled: May 7, 2009Date of Patent: March 4, 2014Assignee: Julius-Maximilians-Universitat WurzburgInventors: Tobias Brixner, Ulrike Selig, Florian Langhojer, Frank Dimler
-
Patent number: 8592389Abstract: In some embodiments, the present invention concerns antisense oligonucleotides against targets of miR-21. In some embodiments, the invention is directed to a method for diagnosing fibrosis and/or fibrosis related diseases and to a method for screening a pharmaceutically active compound for the treatment of fibrosis and/or fibrosis related diseases. The present invention further relates to compositions for use in the treatment, amelioration, and/or prevention of fibrosis. In certain embodiments, the compositions modulate the activity of a miRNA for the treatment, amelioration, and/or prevention of fibrosis. In certain embodiments, the compositions inhibit the activity of miR-21 for the treatment, amelioration, and/or prevention of fibrosis.Type: GrantFiled: June 28, 2012Date of Patent: November 26, 2013Assignee: Julius-Maximilians-Universitat WurzburgInventors: Thomas Thum, Johann Bauersachs, Stefan Engelhardt, Carina Gross
-
Patent number: 8395780Abstract: An optical assembly for use in coherent two- or more-dimensional optical spectroscopy includes a beam splitter that splits a base light pulse into first, second, third and fourth light pulse and a delay element that varies the arrival times of the first to fourth light pulses at a sample location with respect to each other. The beam splitter includes a cross-grating a first reflector arranged to receive the first to fourth light pulses emerging from the cross-grating and to reflect the same in parallel to each other, a second reflector arranged to receive the first to fourth light pulses from the delay element and to focus the same at the sample location, wherein the delay element is arranged between first and second reflectors. Also shown is an apparatus including such optical assembly and a method for carrying out two- or more-dimensional optical spectroscopy using the assembly.Type: GrantFiled: December 8, 2010Date of Patent: March 12, 2013Assignee: Julius-Maximilians-Universitat WurzburgInventors: Tobias Brixner, Ulrike Selig, Florian Langhojer, Carl-Friedrich Schleuβner
-
Publication number: 20130018084Abstract: In some embodiments, the present invention concerns antisense oligonucleotides against targets of miR-21. In some embodiments, the invention is directed to a method for diagnosing fibrosis and/or fibrosis related diseases and to a method for screening a pharmaceutically active compound for the treatment of fibrosis and/or fibrosis related diseases. The present invention further relates to compositions for use in the treatment, amelioration, and/or prevention of fibrosis. In certain embodiments, the compositions modulate the activity of a miRNA for the treatment, amelioration, and/or prevention of fibrosis. In certain embodiments, the compositions inhibit the activity of miR-21 for the treatment, amelioration, and/or prevention of fibrosis.Type: ApplicationFiled: June 28, 2012Publication date: January 17, 2013Applicant: JULIUS-MAXIMILIANS-UNIVERSITAT WURZBURGInventors: Thomas Thum, Johann Bauersachs, Stefan Engelhardt, Carina Gross
-
Publication number: 20120288513Abstract: Embodiments of the present invention provide for novel peptides of use for detection and/or inhibition of anti-?1-adrenergic receptor antibodies. Certain embodiments concern uses of cyclic and/or linear peptides. In other embodiments, the present invention relates to novel peptides of use in diagnostic and/or pharmaceutical compositions. Some embodiments concern diagnosing and/or treating cardiac conditions. Cardiac conditions of the instant invention can concern infectious heart disease, non-infectious heart disease, ischemic heart disease, non-ischemic heart disease, inflammatory heart disease, myocarditis, cardiac dilatation, idiopathic cardiomyopathy, idiopathic dilated cardiomyopathy, immune-cardiomyopathy, heart failure, and any cardiac arrhythmia condition.Type: ApplicationFiled: April 18, 2012Publication date: November 15, 2012Applicant: JULIUS-MAXIMILIANS-UNIVERSITAT WURZBURGInventors: Roland JAHNS, Valérie JAHNS, Martin J. LOHSE, Dieter PALM
-
Publication number: 20120288870Abstract: Embodiments of the present invention provide for novel peptides of use for detection and/or inhibition of anti-?1-adrenergic receptor antibodies. Certain embodiments concern uses of cyclic and/or linear peptides. In other embodiments, the present invention relates to novel peptides of use in diagnostic and/or pharmaceutical compositions. Some embodiments concern diagnosing and/or treating cardiac conditions. Cardiac conditions of the instant invention can concern infectious heart disease, non-infectious heart disease, ischemic heart disease, non-ischemic heart disease, inflammatory heart disease, myocarditis, cardiac dilatation, idiopathic cardiomyopathy, idiopathic dilated cardiomyopathy, immune-cardiomyopathy, heart failure, and any cardiac arrhythmia condition.Type: ApplicationFiled: April 18, 2012Publication date: November 15, 2012Applicant: JULIUS-MAXIMILIANS-UNIVERSITAT WURZBURGInventors: Roland JAHNS, Valérie JAHNS, Martin J. LOHSE, Dieter PALM
-
Patent number: 8277798Abstract: The present invention relates to the use of cells containing in their genome a specific DNA molecule, as cytopathic agents able to inhibit the proliferation of cells, when these proliferative cells are contacted with the cells containing the above-mentioned DNA molecule.Type: GrantFiled: May 10, 2007Date of Patent: October 2, 2012Assignees: Institut National de la Recherche Agronomique, Bayerische Julius-Maximilians-Universitat WurzburgInventors: Eric Oswald, Jörg Hacker, Jean Philippe Nougayrede, Ulrich Dobrindt, Frédéric Taieb, Fabrice Pierre
-
Patent number: 8236777Abstract: The present invention relates to a promoter region of a microRNA, the use of a microRNA, in particular miR-21, and related elements for the diagnosis and for the manufacture of a medicament for the treatment and/or prevention of fibrosis and/or fibrosis related diseases. Additionally, the invention concerns antisense oligonucleotides against targets of miR-21. A cell deficient for miR-21, the promoter region and targets of miR-21 and a knock-out organism thereof are also encompassed. Finally, the invention is directed to a method for diagnosing fibrosis and/or fibrosis related diseases and to a method for screening a pharmaceutically active compound for the treatment of fibrosis and/or fibrosis related diseases. The present invention further relates to compositions for use in the treatment, amelioration, and/or prevention of fibrosis. In certain embodiments, the compositions modulate the activity of a miRNA for the treatment, amelioration, and/or prevention of fibrosis.Type: GrantFiled: February 26, 2009Date of Patent: August 7, 2012Assignee: Julius-Maximilians-Universitat WurzburgInventors: Thomas Thum, Johann Bauersachs, Stefan Engelhardt, Carina Gross
-
Publication number: 20120189613Abstract: The present invention relates to a pharmaceutical composition comprising an inhibitor of STIM2 or an inhibitor of STIM2-regulated plasma membrane calcium channel activity and optionally a pharmaceutically acceptable carrier, excipient and/or diluent. Furthermore, the present invention relates to an inhibitor of STIM2 or an inhibitor of STIM2-regulated plasma membrane calcium channel activity for the treatment and/or prevention of a neurological disorder associated with pathologically increased cytosolic calcium concentrations. Also disclosed are methods of treating and/or preventing a neurological disorder associated with pathologically increased cytosolic calcium concentrations comprising administering a pharmaceutically effective amount of an inhibitor of STIM2 or of an inhibitor of STIM2-regulated plasma membrane calcium channel activity to a subject in need thereof.Type: ApplicationFiled: May 28, 2010Publication date: July 26, 2012Applicant: JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURGInventors: Bernhard Nieswandt, Guido Stoll
-
Patent number: 8207133Abstract: The present invention relates to the use of a regulatory protein RS1 fragment or a nucleic acid molecule encoding said regulatory protein RS1 fragment for the preparation of a pharmaceutical composition for the amelioration, prevention and/or treatment of a metabolic disease or a secondary disorder caused by a (pathological) modification of homeostasis, wherein said RS1 fragment is characterized in comprising at least 3 consecutive amino acid residues as comprised in the amino acid sequence S-D-S-D-R-I-E-P (Serine-Aspartic acid-Serine-Aspartic acid-Arginine-Isoleucine-Glutamic acid-Proline) (SEQ ID NO: 9) or derivatives thereof.Type: GrantFiled: March 31, 2006Date of Patent: June 26, 2012Assignee: Julius-Maximilians-Universitat WurzburgInventors: Herman Koepsell, Alexandra Vernaleken
-
Publication number: 20120100151Abstract: The invention concerns antibodies or fragments thereof that are directed against a Staphylococcus aureus epitope.Type: ApplicationFiled: May 18, 2010Publication date: April 26, 2012Applicant: JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURGInventors: Knut Ohlsen, Udo Lorenz
-
Publication number: 20110157594Abstract: An optical assembly for use in coherent two- or more-dimensional optical spectroscopy includes a beam splitter that splits a base light pulse into first, second, third and fourth light pulse and a delay element that varies the arrival times of the first to fourth light pulses at a sample location with respect to each other. The beam splitter includes a cross-grating a first reflector arranged to receive the first to fourth light pulses emerging from the cross-grating and to reflect the same in parallel to each other, a second reflector arranged to receive the first to fourth light pulses from the delay element and to focus the same at the sample location, wherein the delay element is arranged between first and second reflectors. Also shown is an apparatus including such optical assembly and a method for carrying out two- or more-dimensional optical spectroscopy using the assembly.Type: ApplicationFiled: December 8, 2010Publication date: June 30, 2011Applicant: Julius-Maximilians-Universität WürzburgInventors: Tobias Brixner, Ulrike Selig, Florian Langhojer, Carl-Friedrich Schleussner
-
Publication number: 20110141467Abstract: An apparatus and a method for coherent multi-dimensional optical spectroscopy employs a beam splitter for splitting a base light pulse into at least first to fourth light pulses, three of which are suitable for interaction with a sample, lens system focuses the first to fourth light pulses at a sample site, and an optical delay varies the arrival times of the first to fourth light pulses at the sample. A detector detects an interference signal. The beam splitter is a non-diffractive optical element. The light pulses, at least along part of their light paths, are guided pairwisely such that changes in the optical path length due to vibration of the beam splitter or due to the delay element are identical for each pair of pulses, where the pulse pairs compensate for any change in the interference signal due to a change of the arrival times of the pair of pulses.Type: ApplicationFiled: May 7, 2009Publication date: June 16, 2011Applicant: Julius-Maximilians-Universität WürzburgInventors: Tobias Brixner, Ulrike Selig, Florian Langhojer, Frank Dimler